PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsEnoxaparin
Enoxaparin sodium
Enoxaparin, Inhixa, Lovenox (enoxaparin sodium) is an oligosaccharide pharmaceutical. Enoxaparin sodium was first approved as Lovenox (preservative free) on 1993-03-29. It is used to treat myocardial infarction, postoperative complications, pulmonary embolism, thromboembolism, and thrombophlebitis amongst others in the USA. It has been approved in Europe to treat venous thromboembolism. The pharmaceutical is active against antithrombin-III.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Enoxaparin, Lovenox (discontinued: Lovenox)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Enoxaparin sodium
Tradename
Company
Number
Date
Products
LOVENOX (PRESERVATIVE FREE)SanofiN-020164 RX1993-03-29
7 products, RLD
LOVENOXSanofiN-020164 RX2003-01-23
1 products, RLD
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
enoxaparin sodiumANDA2025-05-26
enoxiluv kitunapproved drug other2024-10-05
lovenoxNew Drug Application2025-06-03
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
B01: Antithrombotic agents
B01A: Antithrombotic agents
B01AB: Heparin group antithrombotic drugs
B01AB05: Enoxaparin
HCPCS
Code
Description
J1650
Injection, enoxaparin sodium, 10 mg
Clinical
Clinical Trials
462 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThromboembolismD013923274214
Venous thromboembolismD054556EFO_0004286I74272212
ThrombosisD013927111328
Venous thrombosisD020246I82.4011327
Acute coronary syndromeD054058EFO_0005672224
Unstable anginaD000789EFO_1000985I20.0112
ObesityD009765EFO_0001073E66.911
Renal dialysisD006435EFO_0010690Z99.211
Atrial fibrillationD001281EFO_0000275I48.011
SyndromeD01357711
Show 4 more
Indications Phases 3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovarian neoplasmsD010051EFO_0003893C5611
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThrombocytopeniaD013921HP_0001873D69.611
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEnoxaparin sodium
INNenoxaparin sodium
Description
Enoxaparin sodium, sold under the brand name Lovenox among others, is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein. It is also used during hemodialysis.
Classification
Oligosaccharide
Drug classheparin derivatives and low molecular weight (or depolymerized) heparins
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID679809-58-6
RxCUI
ChEMBL IDCHEMBL1201476
ChEBI ID
PubChem CID772
DrugBankDB01225
UNII ID8NZ41MIK1O (ChemIDplus, GSRS)
Target
Agency Approved
SERPINC1
SERPINC1
Organism
Homo sapiens
Gene name
SERPINC1
Gene synonyms
AT3
NCBI Gene ID
Protein name
antithrombin-III
Protein synonyms
serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1, Serpin C1, serpin peptidase inhibitor clade C member 1, serpin peptidase inhibitor, clade C (antithrombin), member 1
Uniprot ID
Mouse ortholog
Serpinc1 (11905)
antithrombin-III (P32261)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
£
Enoxaparin Amphastar Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Lovenox Sanofi
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Enoxaparin sodium
+
Enoxaparin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
Black-box warning for: Enoxaparin sodium, Enoxiluv kit, Lovenox
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
37,231 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use